Education
About Us
Working with TipRanks
Follow Us
Quanterix Corporation (QTRX)
NASDAQ:QTRX
QTRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.67 - $19.18
Previous CloseN/A
Volume125.22K
Average Volume (3M)792.53K
Market Cap
$228.08M
Enterprise Value$158.05M
Total Cash (Recent Filing)$24.56M
Total Debt (Recent Filing)$9.22M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 13, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding38,789,024
10 Day Avg. Volume689,380
30 Day Avg. Volume792,528
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.04
Price to Cash Flow (P/CF)-16.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.95
Enterprise Value/Ebitda-3.24
Forecast
1Y Price Target
$13.13Price Target Upside123.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Quanterix News
PremiumCompany Announcements
Quanterix Appoints William Donnelly as New Chairman
PremiumCompany Announcements
Quanterix’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Quanterix Reports Strong Revenue Growth and Strategic Expansion---
Bulls Say, Bears Say
Bulls Say
Alzheimer's Diagnostics MarketThe $9 billion Alzheimer's diagnostics market remains a key source of upside for Quanterix.
New Product LaunchesNew product launches and the Accelerator lab could help offset challenges faced by Quanterix.
Oncology And Immunology ResearchThe acquisition strengthens QTRX position in the oncology and immunology end-markets with translational research offerings.
Bears Say
Academic Market ChallengesU.S. academic funding uncertainty could impact Quanterix's near-term performance.
Investor SentimentNegative investor sentiment on Quanterix's merger with Akoya Biosciences may negatively impact share price performance going forward.
Market CompetitionAKYA is potentially losing share to translational entrants including TECH's Lunaphore and BRKR's CellScape, and the deal would likely complicate QTRX's path to the AD Dx market.
---
Ownership Overview
7.34% Insiders
19.40% Mutual Funds
<0.01% Other Institutional Investors
61.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $4.67 and its highest was $19.18 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $228.08M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is May 13, 2025 which is in 16 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on Mar 17, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.255 by -$0.045.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.44.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 38,789,024 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.255. Following the earnings report the stock price went down -1.786%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
---
Quanterix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.13 (123.30% Upside)
$13.13 (123.30% Upside)
Hedge Fund Trend
Decreased
By 587.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.28%
12-Months-Change
Fundamentals
Return on Equity
-11.33%
Trailing 12-Months
Asset Growth
-3.93%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
---
QTRX Company Deck
---
QTRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Quanterix demonstrated strong growth in revenue and margins, supported by strategic investments and expansion efforts. However, challenges in the academic market and specific regional declines present notable headwinds. The overall sentiment is balanced with both positive growth indicators and concerns about near-term market volatility.Read More>---
QTRX Stock 12 Month Forecast
Average Price Target
$13.13
▲(123.30% Upside)
Technical Analysis
Best Analysts Covering QTRX
1 Year
1 Year Success Rate
4/19 ratings generated profit
1 Year Average Return
-36.35%
reiterated a buy rating last month
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 21.05% of your transactions generating a profit, with an average return of -36.35% per trade.
---